• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human VEGFR2/KDR protein (Myc Tag, His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

Myc Tag, His Tag

Activity

not tested

Cat no : Eg0218

Validation Data Gallery

  • Purity of Recombinant Human VEGFR2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Human VEGFR2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Human VEGFR2 protein Ala20-Glu764 (Accession# P35968-1) with a Myc tag and a His tag at the C-terminus.
GeneID 3791
Accession P35968-1
PredictedSize 88.6 kDa
SDS-PAGE 100-150 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

VEGFR2, also named as KDR, FLK1 and CD309, is one of the two tyrosine kinase receptors involved in angiogenesis. VEGFR2 is mainly distributed in vascular endothelial cells, lymphatic endothelial cells, and embryonic precursor cells, and can bind to VEGF-A, VEGF-C, and VEGF-D. When activated by its ligand VEGF, VEGFR2 promotes neighbouring vessel formation to facilitate the delivery of growth factors, nutrients and oxygen for cancer proliferation, migration, metastasis and survival. VEGF and VEGFR2 mediated angiogenesis contributes to the aggressive natures and leads to high mortality rate in gastric cancer.

References:

1. Xinrong Wang. et al. (2020). Front Cell Dev Biol. 8:599281
2. Michael Simons. et al. (2016). Nat Rev Mol Cell Biol. 17(10):611-25.
3. Jing Yu. et al. (2016). J Hematol Oncol. 9(1):111.
4. Seong Ah Park.et al. (2018). BMB Rep. 51(2):73-78.